A Mass Balance Study of ¹⁴C‐Labeled JTZ‐951 (Enarodustat), a Novel Orally Available Erythropoiesis‐Stimulating Agent, in Patients With End‐Stage Renal Disease on Hemodialysis.

Autor: Pai, Sudhakar M., Connaire, Jeffrey, Yamada, Hiroyuki, Enya, Seiji, Gerhardt, Barbara, Maekawa, Michihide, Tanaka, Hiromasa, Koretomo, Ryosuke, Ishikawa, Tomohiro

Publikováno v: Clinical Pharmacology in Drug Development; Aug2020, Vol. 9 Issue 6, p728-741, 14p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A Mass Balance Study of ¹⁴ C-Labeled JTZ-951 (Enarodustat), a Novel Orally Available Erythropoiesis-Stimulating Agent, in Patients With End-Stage Renal Disease on Hemodialysis.

Autor: Pai SM; Clinical Pharmacology, Akros Pharma Inc, Princeton, New Jersey, USA., Connaire J; DaVita Clinical Research, Minneapolis, Minnesota, USA., Yamada H; Clinical Pharmacology, Pharmaceutical Division, Japan Tobacco Inc, Tokyo, Japan., Enya S; Drug Metabolism and Pharmacokinetics, Central Pharmaceutical Research Institute, Japan Tobacco Inc, Osaka, Japan., Gerhardt B; Clinical Operations, Akros Pharma Inc, Princeton, New Jersey, USA., Maekawa M; Drug Metabolism and Pharmacokinetics, Central Pharmaceutical Research Institute, Japan Tobacco Inc, Osaka, Japan., Tanaka H; Clinical Pharmacology, Pharmaceutical Division, Japan Tobacco Inc, Tokyo, Japan., Koretomo R; Clinical Development, Pharmaceutical Division, Japan Tobacco Inc, Tokyo, Japan., Ishikawa T; Drug Metabolism and Pharmacokinetics, Central Pharmaceutical Research Institute, Japan Tobacco Inc, Osaka, Japan.

Publikováno v: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2020 Aug; Vol. 9 (6), pp. 728-741. Date of Electronic Publication: 2019 Dec 25.